Amgen's earnings call highlighted strong financial performance in 2013, with revenue and EPS growth exceeding expectations.  Management expressed confidence in 2014's data flow from their pipeline, particularly regarding evolocumab, and projected solid revenue and EPS growth.  However, the call also hinted at potential competitive pressures and uncertainties stemming from the need for outcome data before drug approval, affecting the near-term stock price.
[1]
